Novavax (NVAX) Expected to Post Earnings on Thursday

Novavax (NASDAQ:NVAX) is projected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Novavax to post earnings of ($0.3459) per share and revenue of $54.20 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.06. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The business had revenue of $56.70 million during the quarter, compared to the consensus estimate of $52.51 million. During the same quarter last year, the firm posted $0.62 EPS. The business’s revenue was down 76.2% compared to the same quarter last year. On average, analysts expect Novavax to post ($0.38) EPS for the current fiscal year and $0.14 EPS for the next fiscal year.

Novavax Stock Up 3.0%

Shares of NASDAQ NVAX opened at $10.32 on Thursday. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -6.79 and a beta of 2.44. Novavax has a 52 week low of $6.20 and a 52 week high of $13.39. The firm has a 50-day moving average price of $10.39 and a 200 day moving average price of $9.27.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on NVAX shares. Citigroup reaffirmed a “sell” rating and issued a $8.00 target price (up from $7.00) on shares of Novavax in a report on Thursday, October 15th. Zacks Research downgraded Novavax from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Wall Street Zen raised Novavax from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Weiss Ratings reiterated a “sell (d)” rating on shares of Novavax in a research report on Tuesday, August 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Novavax in a research report on Tuesday. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $12.33.

Novavax Company Profile

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.